Phase 2 trials for NV-387 are on deck — and Zacks just slapped a $7
valuation on this tiny biotech. Eyes on this one 👀 ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏




 

_You are receiving this email because you are subscribed to MORNING
WATCHLIST FROM BEHIND THE MARKETS. If you no longer wish to receive
these partner emails, please unsubscribe
[[link removed]]
here. This message is from Equiscreen._

-------------------------

NANOVIRICIDES (NYSE: NNVC) [[link removed]] IS POISED
FOR EXPLOSIVE BREAKOUT AS NV-387 ADVANCES TO PHASE 2 TRIALS TARGETING
MPOX, MEASLES, AND RESPIRATORY VIRUSES!

ZACKS SMALL CAP RESEARCH ISSUES $7 VALUATION!
[[link removed]]

[NNVC logo] [[link removed]]

_A Revolutionary Broad-Spectrum Antiviral Platform Gears Up to Disrupt
Multi-Billion-Dollar Markets in Biodefense, Infectious Disease, and
Global Health…._

_
_

Greetings All,

NANOVIRICIDES, INC. (NYSE: NNVC) is emerging as one of the most
exciting small-cap biotech stories heading into 2026. With its lead
drug candidate, NV-387, now preparing for Phase 2 human
trials, NNVC is redefining the boundaries of antiviral therapy with
a bold mission — TO DELIVER THE WORLD’S FIRST BROAD-SPECTRUM
ANTIVIRAL THAT DESTROYS VIRUSES _BEFORE_ THEY INFECT CELLS.

As measles outbreaks sweep the U.S., and the orthopoxvirus family
(MPox/Smallpox) resurfaces as a global concern, NV-387 is stepping
into the spotlight as a _clinically validated, ready-for-action
therapy_. 

This innovative nanomedicine could become the defining biotech success
story of the decade — and Wall Street is beginning to take notice.

THE #1 REASON TO WATCH NOW…

According to Zacks Small Cap Research, NANOVIRICIDES (NYSE: NNVC) is
entering a pivotal valuation phase as it prepares for Phase 2 clinical
trials of NV-387. 

The firm has issued a valuation of $7 on NNVC which can be
seen HERE [[link removed]].

ZACKS ANALYSTS HIGHLIGHT THAT THE COMPANY’S LEAD CANDIDATE COULD
UNLOCK SIGNIFICANT VALUE THROUGH MULTIPLE COMMERCIAL PATHWAYS —
including MPox treatment, U.S. biodefense stockpile procurement for
smallpox, and broad respiratory virus indications. 

NNVC’S proven safety data, broad antiviral efficacy in multiple
animal models, and advanced regulatory positioning set it apart from
typical early-stage peers. 

Financially, the company exited fiscal year 2025 with approximately
$1.6 million in cash, later raising an additional $1.25 million
through its at-the-market facility to strengthen its runway. 

ZACKS EMPHASIZES THAT POSITIVE DATA FROM THE UPCOMING MPOX PHASE 2
TRIAL COULD RAPIDLY TRANSFORM NNVC’S VALUATION PROFILE —
POSITIONING THE COMPANY FOR STRATEGIC PARTNERSHIPS, NON-DILUTIVE
GOVERNMENT FUNDING VIA BARDA, AND POTENTIAL INCLUSION IN THE U.S.
STRATEGIC NATIONAL STOCKPILE.  

In short, Zacks sees NV-387 as a catalyst capable of
redefining NANOVIRICIDES’ market potential. 

CRISIS CREATES OPPORTUNITY: THE MEASLES EMERGENCY…

The U.S. faces its most severe measles resurgence in over three
decades — with outbreaks expanding across South Carolina, Arizona,
Utah, and Nevada. Globally, nations like Canada, Israel, and New
Zealand are bracing for renewed epidemics. As vaccination coverage
declines, the world needs an immediate therapeutic solution —
and NANOVIRICIDES’ NV-387 may be that solution.

NV-387’s mechanism is simple yet revolutionary: it binds, traps, and
neutralizes viruses in the bloodstream, preventing them from infecting
human cells. IN PRECLINICAL STUDIES, IT BOOSTED SURVIVAL BY 130% IN
MEASLES MODELS WHILE PROTECTING LUNGS FROM IMMUNE-MEDIATED DAMAGE —
A MAJOR LEAP IN ANTIVIRAL SCIENCE!

THE SCIENCE THAT COULD REDEFINE MEDICINE…

Built on THERACOUR® NANOMEDICINE TECHNOLOGY, NV-387 uses
nano-polymer micelles to mimic human cell receptors (heparan-sulfate
proteoglycans). WHEN VIRUSES ATTEMPT TO ATTACH, THEY INSTEAD BIND TO
NV-387, WHICH ENGULFS AND DESTROYS THEM.

This “decoy-and-destroy” process makes
NV-387 _resistance-proof_, _mutation-resistant_, and _universally
effective_ against a wide range of viruses — from measles and RSV
to influenza, COVID-19, MPox, and even smallpox. 

UNLIKE VACCINES OR ANTIBODY TREATMENTS, NV-387 ACTS INDEPENDENTLY OF
THE IMMUNE SYSTEM — MAKING IT AN IDEAL DEFENSE FOR IMMUNOCOMPROMISED
AND HIGH-RISK POPULATIONS.

PHASE 2 TRIAL: TAKING AIM AT MPOX AND BEYOND…

NNVC is set to launch a Phase 2 clinical trial for MPox in late 2025
or early 2026 in the Democratic Republic of Congo — the epicenter of
recent MPox outbreaks.

The upcoming study will evaluate 80 hospitalized patients and compare
NV-387 in combination with the standard of care versus standard
treatment alone. The trial is already approved by the regional
regulatory ethics committee (ACOREP) and backed by a leading Contract
Research Organization (CRO).

POSITIVE RESULTS COULD HAVE IMMEDIATE IMPLICATIONS FOR FDA APPROVAL
UNDER THE ANIMAL RULE FOR SMALLPOX, UNLOCKING A $1 BILLION MARKET VIA
THE U.S. STRATEGIC NATIONAL STOCKPILE AND POTENTIAL BARDA FUNDING —
A MAJOR MILESTONE FOR SHAREHOLDER VALUE!

DUAL-TRACK STRATEGY FOR MAXIMUM MARKET IMPACT…

NNVC is executing an aggressive two-track development strategy:

TRACK 1 – MPOX/SMALLPOX BIODEFENSE PATHWAY:

The Phase 2 MPox trial could pave the way for U.S. biodefense
contracts and inclusion in the Strategic National Stockpile.
NV-387’s demonstrated activity against orthopoxviruses
positions NNVC as a top candidate for BARDA support — non-dilutive
government funding that has historically accelerated major biotech
winners.

TRACK 2 – EMPIRIC THERAPY FOR RESPIRATORY VIRUSES:

A “basket-type” Phase 2 trial is also planned to evaluate NV-387
as a front-line empiric therapy for multiple viral respiratory
infections — a first-of-its-kind approach that mirrors how
antibiotics are prescribed. Positive data could establish NV-387 as
the world’s first universal antiviral, treating infections before
the specific virus is even identified.

STRONG CLINICAL FOUNDATION AND EXPANDING PIPELINE…

NV-387 has already cleared Phase 1 safety testing with zero adverse
events. Its oral gummies and syrup formulations provide easy patient
use, particularly for children and those with severe rashes.

Beyond NV-387, NNVC’S expanding pipeline includes NV-HHV-1 for
shingles and preclinical candidates for HIV, Ebola, Rabies, Dengue,
and Hepatitis, all based on the same nanoviricide platform. EACH
REPRESENTS A POTENTIAL MULTI-BILLION-DOLLAR OPPORTUNITY IN ITS OWN
RIGHT.

THE BOTTOM LINE…

NANOVIRICIDES, INC. (NYSE: NNVC) isn’t just another antiviral
developer — it’s pioneering a new class of medicine designed to
neutralize viruses before infection even begins.  

With Phase 2 trials imminent, BARDA partnerships possible, and orphan
drug designations pending, NNVC could soon redefine the antiviral
landscape. And with a $7 valuation, the future looks bright. 

NV-387 MAY VERY WELL BE THE WORLD’S NEXT GREAT ANTIVIRAL DEFENSE —
AND NANOVIRICIDES, INC. (NYSE: NNVC) COULD BE THE TOP NAME IN
BIOTECH TO WATCH IN 2026! [[link removed]]

We are issuing this disclosure in compliance with Section 17(b) of the
Securities Act, which requires us to disclose any compensation
received or expected to be received in cash or in kind in connection
with the purchase or sale of any security.

We would like to inform you that we have received or expect to receive
compensation in connection with the purchase or sale of the securities
of NanoViricides, Inc. (NYSE American: NNVC). The compensation
consists of up to $6,500 and was received/will be received from
Interactive Offers.

This communication should not be considered as an endorsement of the
securities of adviser NanoViricides, Inc. (NYSE American: NNVC) and we
are not responsible for any errors or omissions in any information
provided about the securities of NanoViricides, Inc. (NYSE American:
NNVC) and Interactive Offers.

We encourage you to conduct your own due diligence and research before
making any investment decisions. You should also consult with a
financial advisor before making any investment decisions.

This disclosure is made as of 01/12/2026.

Our mailing address is:
Behind the Markets, LLC
4260 NW 1st Avenue, Suite 55
Boca Raton, FL 33431

Copyright © 2024 Behind the Markets, LLC, All rights reserved.
You're receiving this email as part of your subscription to Behind the
Markets. For more information about our privacy practices, please
review our Privacy Policy
[[link removed]]
or our Legal Notices.
[[link removed]]

Behind the Markets
[[link removed]]

_You are receiving this email because you are subscribed to Morning
Watchlist from Behind the Markets. If you no longer wish to receive
these partner emails, please unsubscribe here
[[link removed]]._

TODAY'S BONUS CONTENT: 5 Stocks That Could Double Your Investment in
2026
[[link removed]]

 _(By clicking this link you agree to receive emails from Trading
Tips and our affiliates. You can opt out at any time. -__ __Privacy
Policy)_ [[link removed]]